
    
      Total study duration is variable depending on treatment and follow-up periods, including 21
      days of screening, and treatment period until disease progression, unacceptable adverse
      reaction or other reason for discontinuation. End of treatment will be 30 days after last
      administration of investigational medicinal product, or before further anti-myeloma therapy,
      whichever comes first; approximately 14 months after first study treatment administration.
    
  